Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Home on the range where the buffalo roam -- Ignore unavailable to you. Want to Upgrade?

To: Sig who wrote (9998)	12/2/2002 8:49:13 AM
From: Venkie	Read Replies (1) \| Respond to of 13815

kaching

To: Sig who wrote (9998)	12/2/2002 9:13:04 AM
From: D.B. Cooper	Read Replies (1) \| Respond to of 13815

Reuters Amgen raises supply of Enbrel, cuts wait list Monday December 2, 8:52 am ET THOUSAND OAKS, Calif., Dec 2 (Reuters) - Amgen (NasdaqNM:AMGN - News) on Monday said it has offered rheumatoid arthritis treatment Enbrel over the past eight weeks to 40,000 more patients on a waiting list for the drug. ADVERTISEMENT Amgen, which paid $10 billion to buy Enbrel's maker Immunex in the largest biotech merger ever, said it has improved efficiencies at the current Enbrel facility to increase supply of the drug. Sales of Enbrel had been limited by the company's ability to produce the product, which has treated over 129,000 patients worldwide over the past four years. Enbrel sales were $762 million in 2001. A spokesman from Wyeth (NYSE:WYE - News), which is co-marketing the product, said there are no more patients on a waiting list for the drug, but the program will continue to enroll patients to ensure access to Enbrel. Amgen is presently seeking FDA approval for a manufacturing facility in Rhode Island that could double the supply of Enbrel. In our long account, good news